Missouri has become the latest state to collect on a $160 million legal settlement between OxyContin maker Purdue Pharma, the federal government and 26 state Medicaid programs. Purdue was settling claims that it marketed OxyContin improperly by using false claims. In this case, Purdue paid Missouri $5.9 million to its Medicaid program. More than half, about $3.4 million, went to the federal government to reimburse it for its share of Medicaid funding, but the remaining $2.5 million went to the state.
To learn more about the settlement:
- read this St. Louis Business Journal item
Related Articles:
IFMPA institutes new pharma marketing rules. Report
Henry Ford bans pharma perks, vendor drop-ins. Report
A flight of pharma marketing fancy. Report